CJC-1295 Without DAC 5mg + IPAMORELIN 5mg 10mg x 10 Vials
$48.68$54.10 (-10%)
CJC-1295 w/o DAC + Ipamorelin 5mg/5mg is a multi-component research listing containing the named peptide identities. Each component requires its own identity and quantity specification; the finished mixture has no single peptide sequence or universal molecular formula. Ipamorelin alone is a different material from a CJC-1295/Ipamorelin blend. For a blend, the amount and identity of each component must be recorded individually, and the total mass should not be treated as the amount of Ipamorelin. This listing uses a vial presentation; finished-format specifications must be distinguished from the reference molecule. Intended exclusively for controlled in vitro laboratory research; not for human or veterinary use.
CJC-1295 w/o DAC + Ipamorelin 5mg/5mg Australia
CJC-1295 w/o DAC + Ipamorelin 5mg/5mg is listed at AU Peptides Shop in a vial presentation. This page brings together the compound identity, reference chemistry and laboratory considerations relevant to this specific catalogue entry. It is intended exclusively for controlled in vitro laboratory research, not personal use.
Product description
Ipamorelin
Ipamorelin is a synthetic peptide described in growth-hormone-secretagogue receptor research. It includes non-proteinogenic residue chemistry, making stereochemistry and exact residue identity relevant to its structural characterisation. Its analytical identity should be distinguished from other peptides grouped under a broad growth-hormone-related catalogue category.
Ipamorelin alone is a different material from a CJC-1295/Ipamorelin blend. For a blend, the amount and identity of each component must be recorded individually, and the total mass should not be treated as the amount of Ipamorelin.
CJC-1295
CJC-1295 is used in catalogue naming for growth-hormone-releasing-hormone-related research peptides. The full designation is important because materials sold with and without a drug-affinity-complex modification are not the same molecular specification. An abbreviated CJC label should be resolved before selecting a structure or formula.
This undifferentiated CJC-1295 listing is not automatically assigned the structure of the DAC-modified molecule. Confirm the exact version, sequence and terminal groups in the product documents. A shared core peptide sequence does not remove the distinction between modified forms.
Chemical information and molecular structure
This is a multi-component material. A single molecular formula, molecular weight or peptide sequence cannot describe the complete preparation. Each identified component requires its own reference, while the mixture requires a component and quantity specification.
| Reference designation | Ipamorelin |
|---|---|
| Selected reference species | Ipamorelin |
| Reference molecular formula | C38H49N9O5 |
| Reference molecular weight | 711.9 g/mol |
| Reference identifier | PubChem CID 9831659 |
| Sequence information | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
View the reference molecular structure in PubChem. The referenced structure identifies a database species; it is not a structural analysis or certificate for the supplied CJC-1295 w/o DAC + Ipamorelin 5mg/5mg.
| Reference designation | CJC-1295 |
|---|---|
| Formula / molecular weight | Require a confirmed sequence, chemical form or construct specification; not assigned from the catalogue label. |
| Sequence information | Multiple components; use component-specific sequence records. |
Reference formula and molecular weight depend on the represented chemical species. Counterions, hydration, oxidation state, terminal modifications and formulation ingredients can change the relationship between a database molecule and the supplied material. Use the named reference species for structural comparison, and use the batch specification for the actual product composition.
Research applications and experimental scope
- Identification of a synthetic secretagogue peptide.
- Stereochemical and impurity profiling.
- Receptor-associated cell assay development.
- Comparative stability and analytical recovery studies.
- Identification of a GHRH-related peptide.
- Comparison of terminal and conjugation modifications.
- Receptor-system studies in an appropriately qualified model.
- Peptide mapping and stability characterisation.
These are laboratory research topics and analytical objectives, not claims that the supplied product has achieved a biological result. Define the experimental question, model and acceptance criteria before comparing materials. A literature observation made with a different sequence, formulation or model cannot establish the performance of this catalogue item.
Analytical characterisation
For CJC-1295 w/o DAC + Ipamorelin 5mg/5mg, a multi-component method must distinguish the named ingredients rather than report only a total chromatographic area. Consider component-specific reference standards, separation selectivity and recovery from the combined matrix. A dominant peak from one ingredient may obscure another ingredient or a degradation product.
Document individual component amounts and the basis on which they are reported. A nominal blend total is not a measured amount for every constituent. If components share analytical signals, use an orthogonal identity approach or a validated separation before assigning the result. Keep the mixture specification separate from the specifications for its individual reference molecules.
Laboratory model and control considerations
An in vitro experiment with Ipamorelin + CJC-1295 should distinguish the test-material response from effects of the vehicle, assay matrix and any additional ingredients. Include the controls appropriate to the study design, and keep the reference standard and test sample traceable to their own preparation records. Where a readout depends on cell viability or matrix composition, assess those factors independently of the primary measurement.
Record the sample identity, selected product option, preparation history and analytical method used for the comparison. Repeatability within one run does not by itself establish specificity or transferability to another model. Report observations within the limits of the experimental system rather than treating an in vitro result as evidence of a clinical benefit.
Supplied format and product specifications
| Product name | CJC-1295 w/o DAC + Ipamorelin 5mg/5mg |
|---|---|
| Catalogue format | vial presentation |
| Quantity wording in listing | 5mg / 5mg |
| Purity / certification | Refer to the relevant batch report; no percentage or certification is assigned without product documentation. |
A vial describes packaging, not proof of lyophilisation or a particular solution composition. Where the supplied material is documented as a lyophilized powder, preserve that description and its batch-specific handling requirements. A mass in a title does not establish final solution volume, concentration or solvent compatibility.
Solubility and matrix compatibility
For Ipamorelin + CJC-1295, use product-specific solubility information and a laboratory method appropriate to the selected presentation. Apparent dispersion is not necessarily complete dissolution, and a visually clear preparation does not establish chemical stability. Assess recovery and matrix compatibility using the measurement required for your experiment.
Where the product contains additional ingredients, distinguish dissolution of the reference compound from extraction of the finished formulation. Record the documented matrix and any observed interference so another analyst can interpret the result. No universal solvent, solubility limit or preparation protocol is assigned from this catalogue name.
Storage and handling
Use the storage conditions specified for the supplied CJC-1295 w/o DAC + Ipamorelin 5mg/5mg batch and presentation. A universal freezer temperature, refrigeration interval or prepared-sample expiry is not assigned from the compound name alone. Obtain the relevant product guidance when storage or sample stability is an acceptance criterion for your work.
Maintain traceable labels and document the handling history relevant to the study. Assess changes in appearance, analytical profile or recovery against a validated method rather than assuming that an unchanged label establishes stability. Aseptic laboratory technique does not by itself demonstrate that a research product is sterile; sterility and related quality attributes require their own evidence.
Related catalogue comparisons
- Ipamorelin 10mg — Shares a named component; composition differs.
- CJC-1295 5mg — Shares a named component; composition differs.
- CJC-1295 + DAC 5mg — Different designation; compare identity separately.
Compare the exact compound, form and quantity in each linked listing. These catalogue relationships do not establish interchangeable materials or recommend combined use.
Australian research enquiries
For CJC-1295 w/o DAC + Ipamorelin 5mg/5mg in Australia, include the complete listing name, required option and any analytical documentation requirements when you contact AU Peptides Shop. Browse the research catalogue for other individually specified materials. Current purchasing options show price and availability; batch evidence should be reviewed separately.
Scientific references
- PubChem reference: Ipamorelin
- Ipamorelin, the first selective growth hormone secretagogue.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Research compliance notice
For controlled in vitro laboratory research only. Not for human or veterinary use. This description provides scientific reference information and does not recommend dosing, administration or treatment. Research-use labelling does not establish regulatory approval or permission for a particular activity under Australian therapeutic-goods requirements.
